Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

NCT00754494 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

Adenomatous Polyp
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage I Colon Cancer
Stage I Rectal Cancer
Stage IIA Colon Cancer
Stage IIA Rectal Cancer
Stage IIB Colon Cancer
Stage IIB Rectal Cancer
Stage IIC Colon Cancer
Stage IIC Rectal Cancer
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Rectal Cancer
Stage IIIC Colon Cancer
Stage IIIC Rectal Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: placebo
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)